AAAAAA

   
Results: 1-9 |
Results: 9
Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer
Authors: Boucard, M Pinguet, F Poujol, S Romieu, G Cupissol, D Astre, C Culine, S Bressolle, F
Citation: M. Boucard et al., Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer, EUR J CANC, 37(18), 2001, pp. 2357-2364
5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas ofunknown primary site
Authors: Culine, S Ychou, M Fabbro, M Romieu, G Cupissol, D
Citation: S. Culine et al., 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas ofunknown primary site, ANTICANC R, 21(2B), 2001, pp. 1455-1457
Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck
Authors: Pivot, X Cals, L Cupissol, D Guardiola, E Tchiknavorian, X Guerrier, P Merad, L Wendling, JL Barnouin, L Savary, J Thyss, A Schneider, M
Citation: X. Pivot et al., Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck, ONCOL-BASEL, 60(1), 2001, pp. 66-71
Cutaneous melanoma
Authors: Negrier, S Fervers, B Bailly, C Beckendorf, V Cupissol, D Dore, JF Dorval, T Garbay, JR Vilmer, C
Citation: S. Negrier et al., Cutaneous melanoma, BR J CANC, 84, 2001, pp. 81-85
Standards, options and guidelines for caring for patients with cutaneous melanomas
Authors: Negrier, S Fervers, B Bailly, C Beckendorf, V Cupissol, D Dore, JF Garbay, JR Vilmer, C Borel, C Boulier, N Cabarrot, E Carrie, C Chevreau, C de Cislain, C Delaunay, MM Depardieu, C Dubois, JB Escande, MC Fraisse, J Parache, RM Philip, T Ravaud, A Sancho-Garnier, H Spatz, A Autier, P Bonnetblanc, JM de Raucourt, S Dreno, B Gouttebel, MC Grange, F Guillot, B Khayat, D Lehmann, M Leroy, D Regal, R Revuz, J Saiag, P Schmutz, JL Truchetet, F Vuillemin, P
Citation: S. Negrier et al., Standards, options and guidelines for caring for patients with cutaneous melanomas, PRESSE MED, 29(23), 2000, pp. 1317-1326
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function
Authors: Massari, C Brienza, S Rotarski, M Gastiaburu, J Misset, JL Cupissol, D Alafaci, E Dutertre-Catella, H Bastian, G
Citation: C. Massari et al., Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function, CANC CHEMOT, 45(2), 2000, pp. 157-164
Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy
Authors: Culine, S Fabbro, M Ychou, M Romieu, G Cupissol, D Pujol, H
Citation: S. Culine et al., Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy, ANN ONCOL, 10(5), 1999, pp. 569-575
Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer
Authors: Pujol, JL Lafontaine, T Quantin, X Reme-Saumon, M Cupissol, D Khial, F Michel, FB
Citation: Jl. Pujol et al., Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer, CHEST, 115(1), 1999, pp. 144-150
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma
Authors: Dorval, T Negrier, S Chevreau, C Avril, MF Baume, D Cupissol, D Oskam, R de Peuter, R Vinke, J Herrera, L Escudier, B
Citation: T. Dorval et al., Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma, CANCER, 85(5), 1999, pp. 1060-1066
Risultati: 1-9 |